Physician profile
Mackenzie Mertz
NPI 1023426806
$4,492.38
in general payments reported to CMS, 2019-2025
30 companies · $32.35 in 2025
The $32.35 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $418 · 2021: $1,351 · 2022: $716 · 2023: $1,058 · 2024: $731 · 2025: $32.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,821.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $929.85 | 2021-2024 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $508.90 | 2019-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $369.56 | 2021-2024 | |
| Lundbeck LLC | $304.64 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $237.29 | 2020-2024 | Fanapt |
| Tris Pharma INC | $233.12 | 2021-2024 | Dyanavel Xr, Quillichew Er, Quillivant |
| Takeda Pharmaceuticals U.S.A., INC. | $221.03 | 2020-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $196.79 | 2020-2024 | Austedo Xr, Uzedy |
| Alkermes, INC. | $167.99 | 2019-2024 | Aristada, Lybalvi |
| Jazz Pharmaceuticals INC. | $158.58 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $153.53 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $116.68 | 2021-2025 | Caplyta |
| Corium, LLC | $92.54 | 2023 | Azstarys |
| Merck Sharp & Dohme LLC | $84.19 | 2021-2023 | Belsomra |
| Eisai INC. | $72.46 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $68.49 | 2023 | Quviviq |
| Neurocrine Biosciences, INC. | $59.71 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $58.52 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $53.00 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $51.45 | 2020 | |
| Axsome Therapeutics, INC. | $47.23 | 2022-2023 | Auvelity |
| Almatica Pharma LLC | $45.68 | 2022 | |
| Biogen, INC. | $44.04 | 2021 | |
| Shire North American Group INC | $41.26 | 2019 | |
| Sunovion Pharmaceuticals INC. | $39.07 | 2020-2021 | |
| Vertical Pharmaceuticals, LLC | $36.63 | 2019-2020 | |
| Neos Therapeutics, LP | $31.37 | 2020 | |
| Harmony Biosciences LLC | $30.03 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $26.72 | 2024 | |
| Adlon Therapeutics L.P. | $12.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mackenzie Mertz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.